The Company plans to present at three upcoming investor conferences, including the 2017 Stifel Dental and Veterinary Conference in New York City, the Jefferies 2017 Global Healthcare Conference in New York City and the William Blair 2017 Growth Stock Conference in Chicago.
The Company announced its first quarter 2017 financial results. For the quarter ended March 31, 2017, Aratana reported total net revenues of $3.8 million and a net loss of $12.6 million or $0.34 diluted loss per share.
The Company announced that it has entered into a securities purchase agreement with several institutional investors in a registered direct offering.
The Company announced that it recently met with the U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) regarding the proposed manufacturing transfer of ENTYCE® (capromorelin oral solution).